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Research on biomarkers of asthma in early 
childhood could be explained by at least three 
reasons. First, asthma diagnosis in young children 
is often full of doubts and demands long-term ob-
servation of patients. Second, decision on chronic 
inhaled corticosteroids (ICS) treatment in many 
cases is questionable, since a common pattern 
of illness in early life is recurrent episodes of 
wheezing separated in time by periods of asymp-
tomatic wellness. Third, the heterogeneity and 
seasonality of asthma symptoms in young child-
ren impede implementation of GINA guidelines 
in real life practice.
Diagnosis of asthma in early childhood is 
based mainly on carefully taken medical histo-
ry. Such an approach utilizes the best available 
tool such as asthma predictive index (API) with 
various modification. Unfortunately, the positive 
predictive value (PPV) for the API is modest and 
significant proportion of children with positive 
API won’t develop asthma in the future [1]. It 
has been shown previously, that the addition of 
exhaled biomarkers and the expression of inflam-
matory genes in peripheral blood in preschoolers 
with recurrent wheeze improved the predictive 
capacity of the API. Complex model including 
API status, volatile organic compounds, and gene 
expression of toll-like receptor-4, catalase, and 
tumor necrosis factor-alfa (TNF-a) was highly 
predictive of asthma (PPV 90%, NPV 89%) [2]. 
One more thing should be pointed out in this 
context. Non–phenotype-directed antagonism 
of TNF-a in general population of adults with 
moderate-to-severe asthma has failed to improve 
asthma outcomes [3]. However, increased expres-
sion of TNF-a in patients with severe asthma has 
been clearly demonstrated [4, 5]. What is more, 
distinct phenotype of a high TNF-a in children 
with moderate-to-severe asthma has been de-
scribed recently [6]. Asthma, also severe, starts 
usually very early in childhood, when clinical 
manifestation might not justify chronic ICS treat-
ment. Therefore, measurements of biomarkers, 
including TNF-a, may be the best approach to 
prevent delay in the final diagnosis and treatment 
with all clinical consequences. 
In the current issue of the journal Chkhaid-
ze et al. present the results of the study aimed 
to determine whether plasma cytokine levels 
during the acute wheezing illness in infants are 
associated with the subsequent development of 
persistent-recurrent wheezing [7]. Observation 
period in this study corresponded with critical 
window for asthma development. What is more 
authors focused on inflammatory response during 
wheezing episodes, currently recognized as 
crucial issue in natural history of asthma. They 
concluded that TNF-a was strongly associated 
with the risk of persistent-recurrent wheezing 
and could serve as asthma biomarker in chil-
dren under 3 years of age. Such a conclusion is 
limited by the study sample size. Odds ratios 
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are probably overestimated due to relatively low 
number of observations. Also multivariate logis-
tic regression analysis, which allow to conclude 
on the independence of associations, usually 
demands significantly higher sample size. Given 
all the limitations, clinical studies are needed to 
determine the role of TNF-a in childhood asthma 
development and its utility in clinical practice. 
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